
Please try another search
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein, which orchestrates the body's antiviral responses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Joseph Tregonning Colliver | 45 | 2023 | CEO & Executive Director |
Stephen T. Holgate | 78 | - | Co-Founder & Member of Scientific Advisory Board |
David Bruce Campbell | 81 | 2006 | Member of Scientific Advisory Board |
Martin Patrick Murphy | 57 | 2025 | Independent Non-Executive Director |
Mark Parry-Billings | - | 2024 | Executive Chairman |
Donna Davies | - | - | Co-Founder & Member of Scientific Advisory Board |
Ratko Djukanovic | - | - | Co-Founder & Member of Scientific Advisory Board |
Felicity Jane Gabbay | 73 | 2022 | Member of Scientific Advisory Board |
John Bradshaw | 61 | 2025 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review